Ken Griffin Black Diamond Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$4.2 - $6.58 $341,460 - $534,954	81,300 Added 1145.07%	88,400 $384,000
Q2 2024 Aug 14, 2024	BUY	$4.65 - $7.39 $9,765 - $15,519	2,100 Added 42.0%	7,100 $33,000
Q1 2024 May 15, 2024	SELL	$2.67 - $5.74 $267 - $574	-100 Reduced 1.96%	5,000 $25,000
Q4 2023 Feb 14, 2024	SELL	$1.77 - $3.03 $11,682 - $19,998	-6,600 Reduced 56.41%	5,100 $14,000
Q3 2023 Nov 14, 2023	BUY	$2.87 - $4.99 $22,673 - $39,421	7,900 Added 207.89%	11,700 $33,000
Q2 2023 Aug 14, 2023	BUY	$1.43 - $6.18 $4,433 - $19,158	3,100 Added 442.86%	3,800 $19,000
Q1 2023 May 15, 2023	SELL	$1.35 - $3.14 $32,400 - $75,360	-24,000 Reduced 97.17%	700 $1,000
Q4 2022 Feb 14, 2023	SELL	$1.27 - $2.51 $54,102 - $106,925	-42,600 Reduced 63.3%	24,700 $44,000
Q3 2022 Nov 14, 2022	BUY	$1.68 - $4.01 $46,536 - $111,077	27,700 Added 69.95%	67,300 $114,000

117

48.8M

1.84M

1.93M

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $95.9M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.